Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...

Wedbush restated their outperform rating on shares of Scholar Rock (NASDAQ:SRRK – Free Report) in a research note published on Wednesday,RTT News reports. They currently have a $47.00 target price on ...

Lisa Wyman brings more than 20 years of leadership and functional experience to new role of Chief Technical and Quality Officer on the Executive Team at Scholar Rock - Ted Myles, Chief Operating ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44.1972 each, resulting in ...

Ted Myles, COO & CFO at Scholar Rock, will remain with the Company through mid-March, and then serve as a Senior Advisor for six months, during the leadership transition. “I am delighted to have ...

The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".

Deep in the Colombian Amazon region of Serrania De La Lindosa, a roughly 12-mile stretch of rock is covered in a vast ...